Market Size and Forecast
The choroidal neovascularization market was valued at USD 2.52 billion in 2025 and is projected to reach USD 4.86 billion by 2034, growing at a CAGR of 7.28%. The market growth is fueled by increasing retinal disease cases, improved diagnostic capabilities, and advances in biologic and laser-based therapies.
The report provides an overview of emerging treatments, market opportunities, and key developments from leading pharmaceutical and healthcare companies.
Market Snapshot
Ongoing innovation in biologics, advanced laser therapies, and early diagnosis are transforming patient outcomes and driving market expansion.
Key Drivers
- Increasing prevalence of age-related and diabetic retinal diseases
• Advances in anti-angiogenic and laser-based therapies
• Rising awareness of early eye disease diagnosis
• Growing number of ophthalmology clinics and research centers
• Expanding healthcare infrastructure in emerging markets
Market Segmentation Overview
The market is divided into treatment type, indication, route of administration, and end user. These categories define the range of therapies and care settings driving industry growth.
By Treatment Type
• Anti-Angiogenic Therapy: Most commonly used for preventing abnormal vessel growth.
• Laser Photocoagulation: Effective in stabilizing vision for selected patients.
• Photodynamic Therapy: Used for precise targeting of retinal damage.
• Verteporfin Sodium: A specialized drug for managing abnormal blood vessels.
• Ranibizumab, Bevacizumab, Aflibercept, Pegaptanib Sodium: Key biologics that improve retinal health and vision stability.
By Indication
• AMD: Major segment affecting older adults.
• DME: Common among diabetic patients.
• CSC, PCV, MMD, Others: Represent various underlying retinal disorders treated with CNV therapies.
By Route of Administration
• Intravitreal: Most common for effective localized treatment.
• Subconjunctival and Periocular: Provide alternative delivery for patient comfort.
• Oral: Used for supplementary treatment.
By End User
• Hospitals: Handle complex and severe cases.
• Ophthalmology Clinics: Offer regular care and treatment.
• Ambulatory Surgical Centers: Support outpatient retinal procedures.
• Research Centers: Conduct trials for next-generation treatments.
Key Players
The market is highly competitive with global pharmaceutical leaders.
• Regeneron Pharmaceuticals Inc.: Offers biologic drugs like aflibercept for retinal care.
• Roche Holding AG: Focused on developing innovative ophthalmic therapies.
• Bayer AG: Known for advanced anti-VEGF drug formulations.
• Novartis AG: Expands its product line in age-related macular treatments.
• Genentech Inc.: Specializes in biologics improving visual outcomes.
Companies are investing in clinical trials, strategic collaborations, and advanced drug development to enhance treatment accessibility.
Regional Dynamics
- North America: Dominates due to early adoption of advanced therapies and strong research presence.
• Europe: Benefits from supportive healthcare regulations and aging population.
• Asia-Pacific: Fastest growth driven by diabetes prevalence and healthcare modernization.
• Latin America: Emerging adoption supported by improved medical access.
• Middle East & Africa: Gradually expanding with increasing healthcare investments.
Market Opportunities and Challenges
Opportunities
• Growth in biologic therapy research
• Increased investments in ophthalmology clinics
• Expanding healthcare coverage in developing countries
• Rising awareness about eye disease prevention
• Technological advancements in treatment delivery
Challenges
• High cost of biologic treatments
• Limited access to specialized care in rural areas
• Complex disease diagnosis procedures
• Stringent regulatory approvals for new drugs
• Shortage of skilled ophthalmic professionals
Future Outlook
The choroidal neovascularization market is evolving rapidly with advancements in biologics, diagnostics, and laser-based treatments. Growing awareness and early disease detection are expected to enhance patient care globally. Continuous innovation by major pharmaceutical players and improved healthcare accessibility will drive steady market growth through 2034.
Information Source: https://www.valuemarketresearch.com/report/choroidal-neovascularization-market
